Cargando…

Intravenous Tranexamic Acid Given at Femoral Fragility Fracture Surgery Reduces Blood Transfusion Requirements Fourfold

AIMS: This study aims to determine whether intraoperative intravenous (IV) tranexamic acid (TXA) affects blood loss following the surgical management of femoral fragility fractures (FFF). METHODS: This was a single centre (university teaching hospital) non-randomised case–control study. There were 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Powell-Bowns, Matilda F. R., Olley, Rhys K., McCann, Conor, Balfour, James R., Brennan, Caitlin M., Peh, Jasmine, Duckworth, Andrew D., Scott, Chloe E. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971041/
https://www.ncbi.nlm.nih.gov/pubmed/36725742
http://dx.doi.org/10.1007/s00268-022-06886-2
_version_ 1784898025199501312
author Powell-Bowns, Matilda F. R.
Olley, Rhys K.
McCann, Conor
Balfour, James R.
Brennan, Caitlin M.
Peh, Jasmine
Duckworth, Andrew D.
Scott, Chloe E. H.
author_facet Powell-Bowns, Matilda F. R.
Olley, Rhys K.
McCann, Conor
Balfour, James R.
Brennan, Caitlin M.
Peh, Jasmine
Duckworth, Andrew D.
Scott, Chloe E. H.
author_sort Powell-Bowns, Matilda F. R.
collection PubMed
description AIMS: This study aims to determine whether intraoperative intravenous (IV) tranexamic acid (TXA) affects blood loss following the surgical management of femoral fragility fractures (FFF). METHODS: This was a single centre (university teaching hospital) non-randomised case–control study. There were 361 consecutive patients with FFF admitted over a 4-month period were included (mean age 81.4yrs; mean BMI 23.5; 73.7% female). Patient demographics, comorbidities, preoperative anticoagulation use, surgical management, intravenous TXA use, perioperative haemoglobin (Hb) and haematocrit, and requirement for blood transfusion were recorded. The primary outcome was postoperative blood transfusion requirement. Secondary outcomes included postoperative day one calculated blood loss (CBL) (using the Nadler and Gross formulae) and fall in Hb (percentage) from preoperative levels; and the incidence of thrombotic events and mortality up to 30 days. RESULTS: Groups were well matched in terms of patient demographics, comorbidities, preoperative anticoagulation use, injury types and surgical management. Intravenous TXA 1 g given at the beginning of surgery at the discretion of the operating team: 178 (49%) received TXA and 183 (51%) did not. The requirement for postoperative blood transfusion was significantly less in the TXA group: 15/178 (8.4%) compared to 58/183 (31.7%) (p < 0.001; Chi square). TXA significantly reduced both the percentage fall in Hb (mean difference 4.3%, p < 0.001) and the CBL (mean difference −222 ml, p < 0.001). There was no difference in VTE (2 vs 1, p = 0.620) or other thrombotic events (2 vs 0, p = 0.244) between groups. CONCLUSION: 1 g of intraoperative intravenous TXA during the surgical management of FFF was associated with reduced rate of transfusion, CBL and the percentage drop in HB. The use of TXA in this study was not randomised, so there could be un-quantifiable bias in the patient selection.
format Online
Article
Text
id pubmed-9971041
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-99710412023-03-01 Intravenous Tranexamic Acid Given at Femoral Fragility Fracture Surgery Reduces Blood Transfusion Requirements Fourfold Powell-Bowns, Matilda F. R. Olley, Rhys K. McCann, Conor Balfour, James R. Brennan, Caitlin M. Peh, Jasmine Duckworth, Andrew D. Scott, Chloe E. H. World J Surg Original Scientific Report AIMS: This study aims to determine whether intraoperative intravenous (IV) tranexamic acid (TXA) affects blood loss following the surgical management of femoral fragility fractures (FFF). METHODS: This was a single centre (university teaching hospital) non-randomised case–control study. There were 361 consecutive patients with FFF admitted over a 4-month period were included (mean age 81.4yrs; mean BMI 23.5; 73.7% female). Patient demographics, comorbidities, preoperative anticoagulation use, surgical management, intravenous TXA use, perioperative haemoglobin (Hb) and haematocrit, and requirement for blood transfusion were recorded. The primary outcome was postoperative blood transfusion requirement. Secondary outcomes included postoperative day one calculated blood loss (CBL) (using the Nadler and Gross formulae) and fall in Hb (percentage) from preoperative levels; and the incidence of thrombotic events and mortality up to 30 days. RESULTS: Groups were well matched in terms of patient demographics, comorbidities, preoperative anticoagulation use, injury types and surgical management. Intravenous TXA 1 g given at the beginning of surgery at the discretion of the operating team: 178 (49%) received TXA and 183 (51%) did not. The requirement for postoperative blood transfusion was significantly less in the TXA group: 15/178 (8.4%) compared to 58/183 (31.7%) (p < 0.001; Chi square). TXA significantly reduced both the percentage fall in Hb (mean difference 4.3%, p < 0.001) and the CBL (mean difference −222 ml, p < 0.001). There was no difference in VTE (2 vs 1, p = 0.620) or other thrombotic events (2 vs 0, p = 0.244) between groups. CONCLUSION: 1 g of intraoperative intravenous TXA during the surgical management of FFF was associated with reduced rate of transfusion, CBL and the percentage drop in HB. The use of TXA in this study was not randomised, so there could be un-quantifiable bias in the patient selection. Springer International Publishing 2023-02-01 2023 /pmc/articles/PMC9971041/ /pubmed/36725742 http://dx.doi.org/10.1007/s00268-022-06886-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Scientific Report
Powell-Bowns, Matilda F. R.
Olley, Rhys K.
McCann, Conor
Balfour, James R.
Brennan, Caitlin M.
Peh, Jasmine
Duckworth, Andrew D.
Scott, Chloe E. H.
Intravenous Tranexamic Acid Given at Femoral Fragility Fracture Surgery Reduces Blood Transfusion Requirements Fourfold
title Intravenous Tranexamic Acid Given at Femoral Fragility Fracture Surgery Reduces Blood Transfusion Requirements Fourfold
title_full Intravenous Tranexamic Acid Given at Femoral Fragility Fracture Surgery Reduces Blood Transfusion Requirements Fourfold
title_fullStr Intravenous Tranexamic Acid Given at Femoral Fragility Fracture Surgery Reduces Blood Transfusion Requirements Fourfold
title_full_unstemmed Intravenous Tranexamic Acid Given at Femoral Fragility Fracture Surgery Reduces Blood Transfusion Requirements Fourfold
title_short Intravenous Tranexamic Acid Given at Femoral Fragility Fracture Surgery Reduces Blood Transfusion Requirements Fourfold
title_sort intravenous tranexamic acid given at femoral fragility fracture surgery reduces blood transfusion requirements fourfold
topic Original Scientific Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971041/
https://www.ncbi.nlm.nih.gov/pubmed/36725742
http://dx.doi.org/10.1007/s00268-022-06886-2
work_keys_str_mv AT powellbownsmatildafr intravenoustranexamicacidgivenatfemoralfragilityfracturesurgeryreducesbloodtransfusionrequirementsfourfold
AT olleyrhysk intravenoustranexamicacidgivenatfemoralfragilityfracturesurgeryreducesbloodtransfusionrequirementsfourfold
AT mccannconor intravenoustranexamicacidgivenatfemoralfragilityfracturesurgeryreducesbloodtransfusionrequirementsfourfold
AT balfourjamesr intravenoustranexamicacidgivenatfemoralfragilityfracturesurgeryreducesbloodtransfusionrequirementsfourfold
AT brennancaitlinm intravenoustranexamicacidgivenatfemoralfragilityfracturesurgeryreducesbloodtransfusionrequirementsfourfold
AT pehjasmine intravenoustranexamicacidgivenatfemoralfragilityfracturesurgeryreducesbloodtransfusionrequirementsfourfold
AT duckworthandrewd intravenoustranexamicacidgivenatfemoralfragilityfracturesurgeryreducesbloodtransfusionrequirementsfourfold
AT scottchloeeh intravenoustranexamicacidgivenatfemoralfragilityfracturesurgeryreducesbloodtransfusionrequirementsfourfold